Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 5,514 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Alzheimer's Disease
Interventions: LY450139, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years and older
Enrollment: 1,537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more

Conditions: Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
Interventions: TXA127, Placebo; Drug
Lead sponsor: Tarix Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Mobile, Alabama • Los Angeles, California • Orange, California + 3 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 150 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 25
States / cities: Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Docetaxel, Imatinib mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Thoracic Surgery
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Aclidinium Bromide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 42
States / cities: Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 33 more

Conditions: Major Depressive Disorder
Interventions: 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 23
States / cities: Lafayette, California • Lemon Grove, California • Oceanside, California + 20 more

Conditions: Cocaine Dependence
Interventions: lisdexamfetamine/Behavior Therapy, placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: DR-1021, Mircette®, Kariva®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Asthma
Interventions: FP 100mcg, FSC 100/50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 141
States / cities: Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Elafin, Placebo; Drug
Lead sponsor: Roham T. Zamanian; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus Type 2
Interventions: aleglitazar, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Chino, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Advanced Metastatic Breast Cancer
Interventions: Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 35
States / cities: Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Obesity
Interventions: S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet; Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 724 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 35 more

Conditions: Schizophrenia
Interventions: BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 21
States / cities: Garden Grove, California • Lemon Grove, California • Orange, California + 17 more

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Complex Regional Pain Syndromes
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Redwood City, California

Conditions: CKD, Chronic Kidney Diseases, Hepcidin, Ergocalciferol, Vitamin D, Iron-deficiency, Anemia
Interventions: Ergocalciferol 50000 UNT, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Hypertension
Interventions: Isosorbide Mononitrate, sustained release, Placebo capsule; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: RGN-137, Placebo; Drug
Lead sponsor: Lenus Therapeutics, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Placebo (blinded), LX9211 (blinded); Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 108
States / cities: Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more

Conditions: Delayed Onset Muscle Soreness
Interventions: Loxoprofen Pain Patch, Placebo Patch, No Treatment; Drug
Lead sponsor: Lead Chemical Co., Ltd.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetic Nephropathies
Interventions: PF-00489791, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 63
States / cities: Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more

Search by objective public record fields.

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

Treatment of Cocaine Dependence With Lisdexamfetamine

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

Advair Pediatric Once-Daily

Subcutaneous Elafin in Healthy Subjects

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

TMS for Complex Regional Pain Syndrome

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy